Amgen To Pump Up R&D Spend In 2006
This article was originally published in The Pink Sheet Daily
Firm expects a 30%-40% increase in R&D expenditure, primarily driven by a significant increase in clinical development and regulatory spend.
You may also be interested in...
The companies plan to submit a BLA for colorectal cancer agent panitumumab later this week.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products